Compare Page
Tesamorelin vs CJC-1295
Quick verdict: Tesamorelin vs CJC-1295 compares two GHRH-pathway compounds with fundamentally different evidence profiles. Tesamorelin is FDA-approved with multiple RCTs demonstrating CT-measured visceral fat reduction. CJC-1295 has limited published clinical data — a single pharmacokinetic study and no body-composition RCTs.[1][2] Both target pituitary GH release through GHRH-receptor activation, but the confidence gap is significant. A related comparison — CJC-1295 ipamorelin vs tesamorelin — adds a ghrelin-pathway compound; that three-way evaluation involves different receptor pathways entirely.
Read the full peptide profiles: Tesamorelin and CJC-1295.
At a Glance: Tesamorelin vs CJC-1295
Who Each One Usually Fits Better
Tesamorelin usually fits better for people who want the strongest available evidence for a GHRH-pathway compound. FDA approval, replicated RCTs, and CT-measured visceral fat reduction data make it the evidence-first choice. The trade-off is cost and accessibility — tesamorelin is a branded pharmaceutical.[1]
CJC-1295 usually fits better for people exploring GH-axis support in a broader recovery and body-composition context who accept a lower evidence threshold. CJC-1295 is more accessible through research and compounding channels but lacks the clinical validation tesamorelin has. Searches for tesamorelin vs CJC-1295 for muscle growth are common — both compounds increase GH pulsatility, but neither has dedicated muscle-hypertrophy RCT data. Many tesamorelin vs cjc-1295 searches are driven by cost and availability comparisons.[2]
Effects Comparison (Practical)
Body composition context: tesamorelin has dedicated visceral fat RCT data. CJC-1295 does not. Any body-composition claims for CJC-1295 are mechanistic inference from GH-axis activation, not direct clinical evidence. This is the fundamental evidence gap in this comparison.
GH release pattern: a key mechanistic difference. Tesamorelin triggers a pulsatile GH pulse (short half-life, preserves somatostatin feedback). CJC-1295 with DAC produces sustained GH elevation over days — a fundamentally different exposure pattern. The “without DAC” variant (CJC-1295 no DAC, also called modified GRF 1-29) has a shorter half-life closer to natural pulsatile release — mechanistically more comparable to tesamorelin.[1][2]
Recovery context: CJC-1295 appears more frequently in recovery-focused discussions, often paired with ipamorelin. Tesamorelin’s clinical positioning has been body composition, not recovery. Neither has strong recovery-specific RCT data.
Safety and Trade-Offs
- Tesamorelin has a formal safety profile from Phase III trials — injection site reactions (20–30%), arthralgia, fluid retention, and glucose effects are documented with incidence rates.
- CJC-1295’s safety profile is based on limited clinical data and user reports. The DAC variant’s sustained GH elevation raises theoretical concerns about prolonged IGF-1 exposure.
- The DAC vs without-DAC distinction matters for CJC-1295: sustained GH elevation (with DAC) has different risk implications than pulsatile release (without DAC).
- Both share GH-axis class effects. Tesamorelin’s are better characterised because of the regulatory data.
Who It’s Not For (Quick Filter)
- People expecting CJC-1295 evidence quality to match tesamorelin — it does not.
- People choosing between them purely on price without considering the evidence gap.
- People seeking dosing protocols — this page is informational context only.
FAQ
Is tesamorelin better than CJC-1295?
In terms of evidence quality, yes — tesamorelin has FDA approval, multiple RCTs, and CT-measured body-composition data. CJC-1295 has one published pharmacokinetic study and no body-composition trials. Whether “better” applies to your specific context depends on goals, budget, and evidence tolerance.
CJC-1295 vs tesamorelin: what about the “without DAC” version?
CJC-1295 without DAC (also called Modified GRF 1-29) has a shorter half-life and produces more pulsatile GH release — mechanistically closer to tesamorelin’s pattern. The DAC variant sustains GH elevation for days. Most comparison discussions should specify which CJC-1295 variant is being referenced.
Can this page provide tesamorelin or CJC-1295 dosage guidance?
No. This page is informational only and does not provide dosing protocols. It focuses on comparison context, evidence quality, and practical trade-offs.
Why is tesamorelin more expensive than CJC-1295?
Tesamorelin (Egrifta SV) is a branded FDA-approved pharmaceutical with Phase III trial investment, regulatory compliance costs, and patent protection. CJC-1295 is available through research and compounding channels without these regulatory costs. The price difference reflects the evidence and regulatory gap.
Can tesamorelin and CJC-1295 be used together?
Both target the GHRH receptor — concurrent use would be mechanistically redundant rather than synergistic. There is no published clinical data on combined use. This page does not provide protocol guidance.
CJC-1295 ipamorelin vs tesamorelin: how does the blend compare?
CJC-1295 + ipamorelin is a popular pairing that combines GHRH-pathway (CJC-1295) and ghrelin-pathway (ipamorelin) stimulation. Tesamorelin is a single GHRH-pathway compound with FDA approval and RCT data. The blend has no published clinical trial data as a combination — the rationale is mechanistic (dual-pathway GH stimulation), not evidence-backed. Tesamorelin alone has stronger clinical validation than the blend.
Tesamorelin vs CJC-1295 no DAC: does removing the DAC change the comparison?
Yes, meaningfully. CJC-1295 without DAC (modified GRF 1-29) has a short half-life (~30 minutes) and produces pulsatile GH release — mechanistically closer to tesamorelin. The DAC variant sustains GH elevation for days, which is a fundamentally different exposure pattern. Most clinical discussions should specify which CJC-1295 variant is being compared.
References
- [1] Falutz J, et al. Effects of tesamorelin on visceral fat reduction in HIV-infected patients. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20581389.
- [2] Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.